Stryker Corp.

SYK-N

NYSE:SYK

257.13
0.28 (0.11%)
Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ...
More at Wikipedia

Analysis and Opinions about SYK-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
April 6, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 6, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Paul Harris, CFA
Price
$248.480
Owned
Yes
TOP PICK
TOP PICK
March 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
March 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
PAST TOP PICK
PAST TOP PICK
February 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Paul MacDonald
Price
$243.700
Owned
Yes
TOP PICK
TOP PICK
February 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Paul MacDonald
Price
$243.700
Owned
Yes
PAST TOP PICK
PAST TOP PICK
December 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
December 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Paul Harris, CFA
Price
$237.060
Owned
Yes
TOP PICK
TOP PICK
October 2, 2020
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 2, 2020
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
Barry Schwartz
Price
$208.300
Owned
Yes
PAST TOP PICK
PAST TOP PICK
October 1, 2020
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 1, 2020
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
Zachary Curry
Price
$206.510
Owned
Yes
TOP PICK
TOP PICK
September 14, 2020
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
September 14, 2020
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
Paul Harris, CFA
Price
$206.130
Owned
Yes
PARTIAL BUY
PARTIAL BUY
August 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

David Driscoll
Price
$188.510
Owned
Yes
BUY
BUY
August 25, 2020
Allan Tong’s Discover Picks Stryker enjoyed a bounce after beating Q2 revenues and earnings a month ago, but has been rangebound between $180 and $205 since Easter. Typical of the other medical device stocks here, it has yet to return to pre-COVID highs of $226, but trades at a 27.44x PE, far more reasonable than peers including Intuitive Surgical. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 25, 2020
Allan Tong’s Discover Picks Stryker enjoyed a bounce after beating Q2 revenues and earnings a month ago, but has been rangebound between $180 and $205 since Easter. Typical of the other medical device stocks here, it has yet to return to pre-COVID highs of $226, but trades at a 27.44x PE, far more reasonable than peers including Intuitive Surgical. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
BUY
BUY
August 20, 2020
Medical devices have had a tough year, as elective surgeries have been put on hold. Will continue to do well as surgeries come back. Steep learning curve when it comes to these products, so that's a risk. But once doctors learn the mechanics, they're repeat users. Demographic play. At a good level here.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 20, 2020
Medical devices have had a tough year, as elective surgeries have been put on hold. Will continue to do well as surgeries come back. Steep learning curve when it comes to these products, so that's a risk. But once doctors learn the mechanics, they're repeat users. Demographic play. At a good level here.
Paul Harris, CFA
Price
$188.530
Owned
Unknown
BUY
BUY
August 11, 2020

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 11, 2020

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

Christine Poole
Price
$191.405
Owned
No
BUY
BUY
July 31, 2020
He just bought a huge chunk this morning. A company that makes medical devices and is the leader in hips, knees and shoulder replacement. The sales force is their moat. It is able to pivot really quickly. They produce the best products, makes good acquisitions and deploys cash well.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
July 31, 2020
He just bought a huge chunk this morning. A company that makes medical devices and is the leader in hips, knees and shoulder replacement. The sales force is their moat. It is able to pivot really quickly. They produce the best products, makes good acquisitions and deploys cash well.
Barry Schwartz
Price
$193.300
Owned
Yes
TOP PICK
TOP PICK
July 21, 2020
They make medical and surgical equipment in orthopedics. They just bought a hands-and-ankles medical company. Most elective surgeries were postponed in the pandemic, but are slowly coming back now which benefits SYK. Salespeople are very knowledgeable about their products. Doctors remain loyal to SYK's products and won't switch to another company. (Analysts’ price target is $205.79)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
July 21, 2020
They make medical and surgical equipment in orthopedics. They just bought a hands-and-ankles medical company. Most elective surgeries were postponed in the pandemic, but are slowly coming back now which benefits SYK. Salespeople are very knowledgeable about their products. Doctors remain loyal to SYK's products and won't switch to another company. (Analysts’ price target is $205.79)
Paul Harris, CFA
Price
$192.710
Owned
Yes
TOP PICK
TOP PICK
June 26, 2020
A medical device company. Elective surgeries have been slowed during the pandemic, but will still need to done. Demographics mean this will continue to grow. There is brand loyalty in the space as parts are not easily exchangeable. About 25% of cash flow goes to dividends and the rest towards acquisitions and paying down debt. Yield 1.31% (Analysts’ price target is $205.63)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 26, 2020
A medical device company. Elective surgeries have been slowed during the pandemic, but will still need to done. Demographics mean this will continue to grow. There is brand loyalty in the space as parts are not easily exchangeable. About 25% of cash flow goes to dividends and the rest towards acquisitions and paying down debt. Yield 1.31% (Analysts’ price target is $205.63)
Paul Harris, CFA
Price
$175.860
Owned
Yes
Showing 1 to 15 of 104 entries

Stryker Corp.(SYK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 12

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 12 stock analysts published opinions about SYK-N. 10 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by Paul Harris, CFA on 2021-04-06. Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

12 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2021-04-16, Stryker Corp. (SYK-N) stock closed at a price of $257.13.